Through research, acquisitions, and mergers, Celgene (NASDAQ: [[ticker:CELG]]) has built a robust product portfolio and drug pipeline in hematology and oncology. The Summit, NJ-based company has more than 4,000 employees worldwide, including substantial operations in San Diego, and is ranked as one of the top 10 fastest growing biotech stocks. The San Diego Biotechnology Network (SDBN) has invited David Webb, Celgene vice president for research and San Diego site director, to present an overview of the company’s San Diego operations. More information and online registration is available here.